AG
FRTX

Algert Global’s Fresh Tracks Therapeutics, Inc. Common Stock FRTX Stock Holding History

Algert Global’s Portfolio FRTX Stock Details FRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-71
Closed -$68K – 413
2016
Q3 		$68K Buy
71
+18
+34% +$22.7K 0.02% 357
2016
Q2 		$75K Buy
+53
New +$68.2K 0.03% 347

Other funds holding FRTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $71.6B AUM 29.66% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Algert Global's FRTX Position: Q4 2016 in Review

Algert Global sold out of Fresh Tracks Therapeutics, Inc. Common Stock (FRTX) in Q4 2016, closing a stake of 71 shares — an estimated $68K sold.

Algert Global first reported a position in FRTX in Q2 2016 and held it in 2 quarters. The position peaked at $75K in Q2 2016. 26 funds tracked by Wall St. Rank hold FRTX as of Q4 2016.

  • Algert Global reported no remaining Fresh Tracks Therapeutics, Inc. Common Stock position as of Q4 2016 after selling out during the quarter.
  • Algert Global sold 71 Fresh Tracks Therapeutics, Inc. Common Stock shares in Q4 2016, an estimated $68K.
  • Algert Global first reported a position in Fresh Tracks Therapeutics, Inc. Common Stock in Q2 2016 and held it in 2 quarters.
  • Algert Global's Fresh Tracks Therapeutics, Inc. Common Stock position peaked at $75K in Q2 2016.
  • 26 funds tracked by Wall St. Rank held Fresh Tracks Therapeutics, Inc. Common Stock as of Q4 2016.

Based on Algert Global's 13F filing for Q4 2016, filed 26 Jan 2017.